lorlatinib - Profile

What are the generic sources for lorlatinib and what is the scope of patent protection?

Lorlatinib is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lorlatinib has one hundred and twenty-five patent family members in fifty countries.

Summary for lorlatinib

International Patents:	125
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lorlatinib

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for lorlatinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No			Y	Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No			Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No				Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No			Y	Y

EU/EMA Drug Approvals for lorlatinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Lorviqua	lorlatinib	EMEA/H/C/004646Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC whose disease has progressed after:alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; orcrizotinib and at least one other ALK TKI.	Authorised	no	no	no	2019-05-06

International Patents for lorlatinib

Country	Patent Number	Title	Estimated Expiration
Portugal	2822953
Lithuania	PA2019519
Cyprus	1118771
China	116063322

Supplementary Protection Certificates for lorlatinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822953	PA2019519	Lithuania		PRODUCT NAME: LORLATINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/19/1355 20190506
2822953	SPC/GB19/055	United Kingdom		PRODUCT NAME: LORLATINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/19/1355 (NI) 20190508; UK PLGB 00057-1674 20190508; UK PLGB 00057-1675 20190508
2822953	LUC00131	Luxembourg		PRODUCT NAME: LORLATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE; AUTHORISATION NUMBER AND DATE: EU/1/19/1355 20190508
2822953	41/2019	Austria		PRODUCT NAME: LORLATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1355 (MITTEILUNG) 20190508

Lorlatinib Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Lorlatinib, a third-generation ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor (TKI), developed by Pfizer, is approved by the FDA for ALK-positive metastatic NSCLC (non-small cell lung cancer) in adult patients. Its complex pharmacology, targeted therapy profile, and expanding indications position it as a significant player in the oncology space. This report assesses the current and projected market landscape, investment opportunities, competitive environment, and future financial trajectory for lorlatinib through 2030.

---

1. Current Market Landscape

1.1 Drug Profile and Indication

Attribute	Details
Brand Name	Lorbrena (Pfizer)
Approved Indication	ALK-positive metastatic NSCLC (US, EU, others)
Approval Date	August 2018 (US FDA)
Administration	Oral tablet
Pharmacological Class	Third-generation ALK TKI
Key Benefits	Overcomes resistance to earlier-generation ALK inhibitors and CNS penetration

1.2 Market Size & Growth Drivers

Metric	2022 Estimate	2027 Projection	CAGR (2022–2027)
Global NSCLC therapy market	~$20 billion	~$34 billion	11.6%
ALK-positive NSCLC prevalence	~3-5% of NSCLC; ~15,000 new cases/year in US	Increasing with diagnostic rigor
Lorlatinib’s share in ALK-positive NSCLC	Currently ~20-25%	Expected to grow to 40-45%

Note: Market data sourced from IQVIA and Evaluate Pharma.

---

2. Market Dynamics and Competitive Environment

2.1 Key Competitors and Differentiators

Competitor	Key Drugs	Market Position	Unique Features
Alectinib (Alecensa, Roche)	ALK inhibitor, first-line use	Market leader in ALK NSCLC	Superior CNS activity (FitzGerald et al., NEJM, 2020)
Brigatinib (Alunbrig, AstraZeneca)	ALK inhibitor	Growing in second-line, also first-line	CNS efficacy and resistance profile
Ceritinib (Zykadia, Novartis)	ALK inhibitor	Established but declining due to newer agents	CNS activity, but more toxicity

Lorlatinib’s Competitive Edge:

• Designed for resistance mutations, including those after earlier TKIs
• Excellent CNS penetration, critical for brain metastases
• Once-daily oral dosing

2.2 Market Share and Adoption Trends

Year	Estimated Market Share of Lorlatinib in ALK NSCLC	Factors Influencing Adoption
2022	20-25%	Awareness, physician preference, efficacy data
2027	40-45%	Expanded indications, head-to-head trials, resistance management

2.3 Regulatory and Policy Influences

• FDA Label updates: Expanded indications based on ongoing trials (e.g., newly approved for frontline in ALK-positive NSCLC, FDA February 2023)
• Pricing and reimbursement: Negotiations vary across regions; high drug prices (approx. $17,000/month in US) impact market penetration.

---

3. Financial Trajectory and Investment Outlook

3.1 Revenue Projections

Year	Projected Global Revenues	Assumptions
2022	~$650 million	Initial launch, expansion in second-line settings
2023-2024	~$1.2–1.8 billion	Growing use in frontline, increased diagnosed cases
2025-2030	$3 billion+	Widespread adoption, potential first-line standard, geographic expansion

Factors Supporting Revenue Growth:

• Expanded indications (frontline, resistance management)
• Increasing global NSCLC prevalence
• Increasing diagnostic rates
• Competitive pricing strategies and reimbursement gains

3.2 R&D Pipeline and Future Indications

Development Stage	Indications	Expected Approval Timeline	Rationale
Phase III ongoing	Pediatric ALK-positive tumors	2024–2025	Expanding label, broader patient base
Preclinical	MET, ROS1 mutations	2024–2026	Broadened targeted therapy use cases

3.3 Risks and Challenges

• Market competition: Alectinib and brigatinib continue strong presences.
• Pricing pressures: Payers may impose restrictions.
• Regulatory delays: Pending approvals or label expansions.
• Resistance development: Tumor resistance remains an ongoing challenge.

---

4. Comparative Analysis and Key Metrics

Parameter	Lorlatinib	Alectinib (Alecensa)	Brigatinib (Alunbrig)
First-line approval	No, primarily second-line, though approved for frontline in US	Yes	Approved for first-line NSCLC systematically
Brain metastases efficacy	High	High	High
Overall Survival (OS) data (2022)	Emerging in trials	Confirmed in some studies	Limited recent data
Price (per month, approx.)	$17,000	$15,500	$13,700

---

5. Strategic Considerations for Investors

5.1 Growth Opportunities

• Diversification into resistance mutation profiles
• Geographic expansion into emerging markets
• Combination therapies with immunotherapies
• Companion diagnostics development

5.2 Investment Pitfalls

• Competitive landscape tightens as other TKIs evolve
• Regulatory hurdles in key markets
• Market saturation in mature indications

5.3 Market Entry & Expansion Strategies

• Alliances with diagnostics firms
• Strategic licensing in emerging markets
• Investment in real-world evidence (RWE) to support expansion

---

6. Conclusion and Outlook

Lorlatinib’s role as a next-generation ALK TKI with CNS penetration ensures a strong position within targeted NSCLC therapy. Accelerating approvals for frontline use and indications beyond ALK-positive NSCLC remain pivotal to its long-term commercial success. Its revenue trajectory indicates potential for substantial growth, conditioned on competitive positioning, regulatory success, and sustained efficacy. Investors should weigh innovative pipeline efforts and market dynamics, keeping in mind the competitive intensity and evolving treatment paradigms.

---

Key Takeaways

• Lorlatinib is projected to reach $3 billion+ in annual revenues by 2030, driven by expanded indications and geographic growth.
• The primary growth drivers include frontline approval, resistance management, and CNS efficacy advantages.
• Competition remains stiff, with alectinib maintaining dominance in some markets but lorlatinib capturing significant second-line and resistance-focused segments.
• The pipeline’s focus on broader patient populations and resistance mutations sustains long-term value.
• Pricing, reimbursement policies, and emerging competitors represent ongoing challenges.

---

FAQs

Q1: How does lorlatinib compare to other ALK inhibitors in CNS activity?

A: Lorlatinib has superior CNS penetration and efficacy compared to earlier-generation ALK inhibitors like crizotinib, enabling it to target brain metastases effectively, which is a key treatment advantage.

Q2: What are the main factors influencing lorlatinib’s market penetration?

A: The key factors include regulatory approvals (especially for frontline use), physician familiarity, reimbursement status, competition from alternative TKIs, and drug pricing.

Q3: What potential market expansion avenues exist for lorlatinib?

A: Expanding into earlier lines of therapy, targeting other ALK mutations, developing combination treatments with immunotherapy, and entering emerging markets are primary avenues.

Q4: How does resistance to lorlatinib develop, and what are the implications?

A: Resistance mechanisms include secondary mutations in ALK and bypass signaling pathways. Addressing resistance requires ongoing R&D, combination therapies, or next-generation inhibitors, constraining long-term exclusivity.

Q5: What are the primary regulatory hurdles for lorlatinib’s future growth?

A: Approvals for new indications, overcoming regional regulatory differences, and maintaining safety profiles are critical. Delays or failures could impact revenue forecasts.

---

References

1. FitzGerald, et al., NEJM, 2020. Efficacy of CNS-penetrant ALK inhibitors in NSCLC.
2. FDA Approvals, 2018–2023.
3. IQVIA, 2022 Data.
4. Evaluate Pharma, Market Forecasts, 2022.
5. Pfizer Corporate Reports, 2022–2023.

Note: All projections are based on publicly available data and industry analyses as of early 2023, with inherent uncertainties linked to market variables and clinical developments.